Biography
Dr. Daniel Sterman is the Director of Pulmonary Medicine and Interventional Pulmonology at NYU Langone. He is a pioneer in gene therapy for mesothelioma, having led clinical trials of intrapleural adenoviral interferon gene therapy — an approach that delivers immune-stimulating genes directly into the pleural space to activate the body's defense against mesothelioma. Dr. Sterman works alongside Dr. Harvey Pass as part of NYU Langone's multidisciplinary mesothelioma program.
Education & Training
- Medical Degree — Case Western Reserve University School of Medicine (Medicine)
- Residency — Hospital of the University of Pennsylvania (Internal Medicine)
- Fellowship — Hospital of the University of Pennsylvania (Pulmonary and Critical Care Medicine)
Specialties & Procedures
Clinical Specialties
- Interventional Pulmonology
- Thoracic Oncology
- Mesothelioma
As a medical oncologist, Dr. Daniel Sterman focuses on non-surgical treatment modalities including chemotherapy, immunotherapy, targeted therapy, and clinical trials.
Board Certifications
- American Board of Internal Medicine — Pulmonary Disease
- American Board of Internal Medicine — Internal Medicine
Research Focus
Intrapleural gene therapy for mesothelioma, immunogene therapy, interventional pulmonary techniques for pleural malignancies, and pleurodesis.
Notable Publications
- Intrapleural adenoviral-mediated interferon gene therapy for malignant pleural mesothelioma. Clinical Cancer Research, 2016.
Treatment Center
Dr. Daniel Sterman practices at NYU Langone Perlmutter Cancer Center in New York, NY.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is gene therapy for mesothelioma?
Dr. Sterman's gene therapy approach delivers genes for immune-stimulating proteins (like interferon) directly into the pleural space using a modified adenovirus. This activates the patient's immune system to attack mesothelioma cells from within the chest cavity.
Does Dr. Sterman work with Dr. Harvey Pass?
Yes. Dr. Sterman and Dr. Pass are part of the multidisciplinary mesothelioma program at NYU Langone, combining Dr. Sterman's pulmonary and gene therapy expertise with Dr. Pass's surgical and biomarker research.